月旦知識庫
 
  1. 熱門:
 
首頁 臺灣期刊   法律   公行政治   醫事相關   財經   社會學   教育   其他 大陸期刊   核心   重要期刊 DOI文章
台灣醫學 本站僅提供期刊文獻檢索。
  【月旦知識庫】是否收錄該篇全文,敬請【登入】查詢為準。
最新【購點活動】


篇名
以作用機轉為基礎把標靶藥物在眼科治療之角色
並列篇名
The Role of Mechanism-Based Target Therapy in Ophthalmology
作者 謝德威王忠鈺劉欣瑜
中文摘要
標靶治療是近年來疾病的新興治療策略,廣義而言是瞄準特定的致病機轉,治療疾病本身並同時降低副作用。本文首先介紹ROCK抑制劑、鈣調磷酸酶抑制劑(calcineurin inhibitors)、整合素抑制劑(integrin inhibitors)、抗血管內皮生長因子藥物(anti-VEGF therapies)等藥物於眼科的應用。接著討論眼科癌症,包括眼內淋巴癌與葡萄膜黑色毒瘤的標靶治療。上述藥物參與的生理作用涵蓋血管新生、免疫反應與致癌機制。本文主要介紹這些標靶藥物的藥理機轉與新藥在疾病治療上的角色,並輔以當前的尚待克服的挑戰與研究目標,期待結合這些基礎藥理機轉與臨床治療上的證據,可指引未來眼科精準治療的方向。
英文摘要
Targeted therapies have become emerging treatment strategies for various ocular diseases. These treatments exploit novel targets and mechanisms with an aim to better control the diseases with reduced adverse effects. In this article, we introduced the application of targeted therapy in ophthalmology, including ROCK (Rho-kinase) inhibitors, calcineurin inhibitors, integrin inhibitors and anti-VEGF (vascular endothelial growth factor) therapies. We also discussed targeted therapies for ocular cancers including primary intraocular lymphoma and uveal melanoma. These topics cover a wide spectrum of biological processes, such as vascular proliferation, immune response and oncogenesis. For each topic, we briefly presented the underlying mechanisms, along with the corresponding drugs and their role in current ocular disease regimens. We further included some ongoing challenges and research directions to solve them. Combining these pharmacological knowledge and clinical evidence may shed light on ideas towards future precise treatments in ophthalmology.
起訖頁 493-498
關鍵詞 標靶治療Rho相關蛋白酶鈣調磷酸酶抑制劑整合素抗血管內皮生長因子眼內淋巴癌葡萄膜黑色毒瘤targeted therapyROCKcalcineurinintegrinVEGFintraocular lymphomauveal melanoma
刊名 台灣醫學  
期數 202107 (25:4期)
出版單位 臺灣醫學會
該期刊-上一篇 標靶藥物、生物製劑和免疫療法在眼科疾病之成效
該期刊-下一篇 標靶藥物、免疫治療、生物製劑的前眼部副作用
 

新書閱讀



最新影音


優惠活動




讀者服務專線:+886-2-23756688 傳真:+886-2-23318496
地址:臺北市館前路28 號 7 樓 客服信箱
Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄